Ausgabe 6/2017
Inhalt (23 Artikel)
The dawn of “immune-revolution” in children: early experiences with checkpoint inhibitors in childhood malignancies
Maurizio Lucchesi, Iacopo Sardi, Gianfranco Puppo, Antonio Chella, Claudio Favre
Telotristat ethyl: proof of principle and the first oral agent in the management of well-differentiated metastatic neuroendocrine tumor and carcinoid syndrome diarrhea
Muhammad Masab, Muhammad Wasif Saif
Phase 1 study of darolutamide (ODM-201): a new-generation androgen receptor antagonist, in Japanese patients with metastatic castration-resistant prostate cancer
Nobuaki Matsubara, Hirofumi Mukai, Ako Hosono, Mai Onomura, Masaoki Sasaki, Yoko Yajima, Kensei Hashizume, Masanobu Yasuda, Miho Uemura, Christian Zurth
Erratum to: Phase 1 study of darolutamide (ODM-201), a new-generation androgen receptor antagonist, in Japanese patients with metastatic castration-resistant prostate cancer
Nobuaki Matsubara, Hirofumi Mukai, Ako Hosono, Mai Onomura, Masaoki Sasaki, Yoko Yajima, Kensei Hashizume, Masanobu Yasuda, Miho Uemura, Christian Zurth
Exposure–response analyses of trastuzumab emtansine in patients with HER2-positive advanced breast cancer previously treated with trastuzumab and a taxane
Chunze Li, Bei Wang, Shang-Chiung Chen, Russell Wada, Dan Lu, Xin Wang, Daniel Polhamus, Jonathan French, Shweta Vadhavkar, Alexander Strasak, Melanie Smitt, Amita Joshi, Meghna Samant, Angelica Quartino, Jin Jin, Sandhya Girish
A rat model of FOLFOX-induced neuropathy: effects of oral dimiracetam in comparison with duloxetine and pregabalin
Lorenzo Di Cesare Mannelli, Mario Maresca, Laura Micheli, Carlo Farina, Michael W. Scherz, Carla Ghelardini
CA19-9 kinetics during systemic chemotherapy in patients with advanced or recurrent biliary tract cancer
Naminatsu Takahara, Yousuke Nakai, Hiroyuki Isayama, Takashi Sasaki, Kei Saito, Kensaku Noguchi, Tatsunori Suzuki, Tomoka Nakamura, Tatsuya Sato, Kazunaga Ishigaki, Ryunosuke Hakuta, Tsuyoshi Takeda, Rie Uchino, Suguru Mizuno, Hirofumi Kogure, Minoru Tada, Kazuhiko Koike
Malignant bone tumors (other than Ewing’s): clinical practice guidelines for diagnosis, treatment and follow-up by Spanish Group for Research on Sarcomas (GEIS)
Andrés Redondo, Silvia Bagué, Daniel Bernabeu, Eduardo Ortiz-Cruz, Claudia Valverde, Rosa Alvarez, Javier Martinez-Trufero, Jose A. Lopez-Martin, Raquel Correa, Josefina Cruz, Antonio Lopez-Pousa, Aurelio Santos, Xavier García del Muro, Javier Martin-Broto
A triplet combination with capecitabine/oxaliplatin/irinotecan (XELOXIRI) plus cetuximab as first-line therapy for patients with metastatic colorectal cancer: a dose escalation study
Yasushi Sato, Masahiro Hirakawa, Hiroyuki Ohnuma, Minoru Takahashi, Tetsuro Okamoto, Koichi Okamoto, Hiroshi Miyamoto, Naoki Muguruma, Tomohisa Furuhata, Ichiro Takemasa, Junji Kato, Tetsuji Takayama
The effects of lapatinib on CYP3A metabolism of midazolam in patients with advanced cancer
Kevin M. Koch, E. Claire Dees, Shodeinde A. Coker, Nandi J. Reddy, Shelby D. Gainer, Nikita Arya, Andrew P. Beelen, Lionel D. Lewis
Population pharmacokinetics of trastuzumab emtansine in previously treated patients with HER2-positive advanced gastric cancer (AGC)
Shang-Chiung Chen, Matts Kagedal, Yuying Gao, Bei Wang, Marie-Laurence Harle-Yge, Sandhya Girish, Jin Jin, Chunze Li
Randomized study of etirinotecan pegol versus irinotecan as second-line treatment for metastatic colorectal cancer
Heinz-Josef Lenz, Philip Philip, Mark Saunders, Tatjana Kolevska, Kalyan Mukherjee, Leslie Samuel, Shailesh Bondarde, Tracy Dobbs, Mary Tagliaferri, Ute Hoch, Alison L. Hannah, Maurice Berkowitz
Exposure-survival analyses of pazopanib in renal cell carcinoma and soft tissue sarcoma patients: opportunities for dose optimization
R. B. Verheijen, L. E. Swart, J. H. Beijnen, J. H. M. Schellens, A. D. R. Huitema, N. Steeghs
Uncommon mutation types of epidermal growth factor receptor and response to EGFR tyrosine kinase inhibitors in Chinese non-small cell lung cancer patients
Kaiyan Chen, Xiaoqing Yu, Haiyang Wang, Zhiyu Huang, Yanjun Xu, Lei Gong, Yun Fan
Phase II study of fixed dose-rate gemcitabine plus S-1 as a second-line treatment for advanced biliary tract cancer
Satoshi Kobayashi, Makoto Ueno, Kazuya Sugimori, Chigusa Morizane, Yasushi Kojima, Kuniyasu Irie, Yoshihiro Goda, Manabu Morimoto, Shinichi Ohkawa
A non-randomized, open-label, single-arm, Phase 2 study of emibetuzumab in Asian patients with MET diagnostic positive, advanced gastric cancer
Daisuke Sakai, Hyun Cheol Chung, Do-Youn Oh, Se Hoon Park, Shigenori Kadowaki, Yeul Hong Kim, Akihito Tsuji, Yoshito Komatsu, Yoon-Koo Kang, Kazunori Uenaka, Sameera R. Wijayawardana, Volker Wacheck, Xuejing Wang, Ayuko Yamamura, Toshihiko Doi
Efficacy of depatuxizumab mafodotin (ABT-414) monotherapy in patients with EGFR-amplified, recurrent glioblastoma: results from a multi-center, international study
Martin van den Bent, Hui K. Gan, Andrew B. Lassman, Priya Kumthekar, Ryan Merrell, Nicholas Butowski, Zarnie Lwin, Tom Mikkelsen, Louis B. Nabors, Kyriakos P. Papadopoulos, Marta Penas-Prado, John Simes, Helen Wheeler, Tobias Walbert, Andrew M. Scott, Erica Gomez, Ho-Jin Lee, Lisa Roberts-Rapp, Hao Xiong, Earle Bain, Peter J. Ansell, Kyle D. Holen, David Maag, David A. Reardon
The potential usefulness of the Response Index in positron emission tomography assessing the therapeutic effect of pre-operative chemotherapy for advanced colorectal cancer
Masatoshi Nomura, Hidekazu Takahashi, Naotsugu Haraguchi, Junichi Nishimura, Taishi Hata, Chu Matsuda, Masakazu Ikenaga, Hirofumi Yamamoto, Kohei Murata, Yuichiro Doki, Masaki Mori, Tsunekazu Mizushima
Ibrutinib does not prolong the corrected QT interval in healthy subjects: results from a thorough QT study
Jan de Jong, Peter Hellemans, James Juhui Jiao, Yuhan Huang, Sofie Mesens, Juthamas Sukbuntherng, Daniele Ouellet
Combination chemotherapy with irinotecan and gemcitabine for taxane/platinum-resistant/refractory ovarian and primary peritoneal cancer: a multicenter phase I/II trial (GOGO-Ov 6)
Kiyoshi Yoshino, Shoji Kamiura, Takeshi Yokoi, Ruriko Nakae, Masami Fujita, Masahiko Takemura, Kazushige Adachi, Akinori Wakimoto, Takamichi Nishizaki, Yasuhiko Shiki, Tateki Tsutsui, Yuki Kanda, Eiji Kobayashi, Kae Hashimoto, Seiji Mabuchi, Yutaka Ueda, Kenjiro Sawada, Takuji Tomimatsu, Tadashi Kimura
Evaluation of the effect of new formulation, food, or a proton pump inhibitor on the relative bioavailability of the smoothened inhibitor glasdegib (PF-04449913) in healthy volunteers
Nagdeep Giri, Lisa H. Lam, Robert R. LaBadie, Joseph F. Krzyzaniak, Hong Jiang, Brian Hee, Yali Liang, M. Naveed Shaik
Treatment-related sinusoidal obstruction syndrome in children with de novo acute lymphoblastic leukemia during intensification
Casey L. McAtee, Netta Schneller, Julienne Brackett, M. Brooke Bernhardt, Eric S. Schafer
PRIMUM NON NOCERE: now and again an echo of DPD with capecitabine
Joseph Ciccolini, Bruno Lacarelle, Gérard Milano